Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery



Status:Completed
Conditions:Cardiology, Ocular, Ocular
Therapuetic Areas:Cardiology / Vascular Diseases, Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:10/14/2017
Start Date:January 2011
End Date:October 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Phase 2 Study of Ozurdex for Combined Pseudophakic Cystoid Macula Edema and Diabetic Macula Edema After Cataract Surgery

The purpose of the study is to determine where a sustained steroid delivery system
(Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients
after Cataract Surgery


Inclusion Criteria:

- DIABETIC PATIENTS WHO DEVELOP CYSTOID MACULA EDEMA AFTER CATARACT SURGERY (WITHIN 4-10
WEEKS AFTER SURGERY

- VISUAL ACUITY WORSE THAN 20/32

Exclusion Criteria:

- VISUAL ACUITY WORSE THAN 20/200

- MODERATE OR SEVERE GLAUCOMA (AS DEFINED AS USING >2 TOPICAL GLAUCOMA MEDIATIONS.

- USE OF SYSTEMIC, PERIOCULAR OR INTRAOCULAR CORTICOSTEROIDS WITHIN 30 DAYS OF
ENROLLMENT
We found this trial at
1
site
Northern California Retina Vitreous Associates
Mountain View, California 94040
?
mi
from
Mountain View, CA
Click here to add this to my saved trials